Omnicell, Inc. (NASDAQ:OMCL) reached a new 52-week high on Friday . The company traded as high as $163.00 and last traded at $163.00, with a volume of 322 shares changing hands. The stock had previously closed at $160.88.
A number of equities research analysts have weighed in on OMCL shares. BTIG Research reaffirmed a “buy” rating and set a $151.49 price objective (down from $165.00) on shares of Omnicell in a report on Tuesday, July 27th. JPMorgan Chase & Co. started coverage on Omnicell in a report on Wednesday, June 9th. They issued a “neutral” rating and a $146.00 target price on the stock. Zacks Investment Research downgraded Omnicell from a “hold” rating to a “sell” rating and set a $162.00 target price on the stock. in a report on Friday, July 9th. Piper Sandler boosted their target price on Omnicell from $152.00 to $188.00 and gave the stock an “overweight” rating in a report on Wednesday, June 23rd. Finally, TheStreet raised Omnicell from a “c+” rating to a “b+” rating in a report on Thursday, July 29th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Omnicell has a consensus rating of “Hold” and a consensus price target of $141.06.
The firm has a fifty day simple moving average of $153.67 and a 200-day simple moving average of $144.01. The company has a current ratio of 3.10, a quick ratio of 2.78 and a debt-to-equity ratio of 0.45. The stock has a market cap of $6.98 billion, a price-to-earnings ratio of 123.52, a P/E/G ratio of 4.97 and a beta of 1.04.
In related news, EVP Scott Peter Seidelmann sold 41,878 shares of the company’s stock in a transaction on Thursday, August 5th. The shares were sold at an average price of $153.05, for a total value of $6,409,427.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Dan S. Johnston sold 31,236 shares of the company’s stock in a transaction on Tuesday, July 20th. The shares were sold at an average price of $151.35, for a total transaction of $4,727,568.60. The disclosure for this sale can be found here. Insiders have sold a total of 96,284 shares of company stock valued at $14,728,766 in the last quarter. Corporate insiders own 2.63% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in OMCL. KB Financial Partners LLC bought a new stake in shares of Omnicell in the 1st quarter valued at $29,000. Certified Advisory Corp bought a new stake in shares of Omnicell in the 1st quarter valued at $32,000. Parkside Financial Bank & Trust increased its position in shares of Omnicell by 141.0% in the 2nd quarter. Parkside Financial Bank & Trust now owns 294 shares of the company’s stock valued at $45,000 after buying an additional 172 shares in the last quarter. Harvest Fund Management Co. Ltd increased its position in shares of Omnicell by 175.9% in the 2nd quarter. Harvest Fund Management Co. Ltd now owns 367 shares of the company’s stock valued at $54,000 after buying an additional 234 shares in the last quarter. Finally, Harbor Investment Advisory LLC increased its position in shares of Omnicell by 22.5% in the 2nd quarter. Harbor Investment Advisory LLC now owns 479 shares of the company’s stock valued at $73,000 after buying an additional 88 shares in the last quarter.
About Omnicell (NASDAQ:OMCL)
Omnicell, Inc engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation.
Read More: What can cause a stock to outperform?
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.